Rare Neurodegenerative Disease Efforts Under the ACT for ALS

This hybrid meeting will provide an opportunity to share the 2024 priorities for Critical Path for Rare Neurodegenerative Diseases (CP-RND) program to provide an update on efforts from the Food and Drug Administration (FDA) and National Institutes of Health (NIH) focused on rare neurodegenerative diseases.

• Efforts within CP-RND 
• Update from FDA on rare neurodegenerative efforts including natural history grants and upcoming opportunities 
• Opportunity to highlight NIH/FNIH efforts to support rare neurogenerative diseases